slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 87,181-87,210
Pages 3,225
Rows per page 30
Component
87,181-87,210 of 96,741
09
MTD = Maximum Tolerated Dose; PR = Partial Response; RECIST = Response Evaluation Criteria in Solid Tumors; ORR = Objective Response Rate.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The chart highlights a subset of patients with significant tumor reduction (boxed area).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
This is a standard oncology 'swimmer's plot' or 'waterfall plot' used to demonstrate clinical efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide uses a logo-grid layout to demonstrate the breadth of university partnerships across various degree categories.Coursera | Results Presentation Deck | 39 slides · Coursera
Conference presentation Investor relations Beat · NeedLoop · Golden Circle1 hit
09
Includes a timeline at the bottom and two bar charts showing RWA and leverage exposure reduction.Credit Suisse | Results Presentation Deck | 44 slides · Credit Suisse
Deck Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
12
The slide uses a horizontal arrow-based timeline to represent strategic phases.Credit Suisse | Results Presentation Deck | 44 slides · Credit Suisse
Deck Investor relations Beat · Satisfaction1 hit
40
Includes a donut chart representing currency mix for capital metrics.Credit Suisse | Results Presentation Deck | 44 slides · Credit Suisse
Deck Investor relations Beat · Action1 hit
07
The chart highlights a 54% five-year annualized TSR for Crocs, Inc.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations Beat · Solution1 hit
19
The slide uses bar charts with trend arrows to visualize growth momentum.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
35
The chart highlights a 54% five-year annualized TSR for Crocs, significantly outperforming the benchmarks.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations Beat · Financials1 hit
04
The slide uses a contrast between the low research/pipeline investment (left) and the high market impact/purchasing power (right) to argue for efficiency.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
05
The slide uses a comparative framework to show market potential by citing historical peak revenues of successful drugs.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · Market Size1 hit
07
The slide uses a numbered list for the thesis points and a separate callout box for milestones.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
08
The slide uses a Gantt-chart style visualization to show the progress of multiple drug candidates across clinical phases.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
09
Includes specific financial terms of the collaboration and regulatory milestones.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
16
Slide 16 of a pitch deck.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
17
The slide uses a structured comparison format to frame the medical problem and the proposed solution.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
18
Mentions Organon as the commercial partner leveraging the NEXPLANON sales team.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The slide highlights a key partnership milestone and the associated financial structure (upfront payment and potential milestones).Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
Includes a line chart of population projections and three circular callouts detailing specific product sales.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
Includes details on milestone payments, royalties, and strategic support from Bayer.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Includes a testimonial quote from a Bayer executive.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
Includes a data table comparing baseline PCT results with Ovaprene PCT results.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a light blue callout box to group the product benefits and highlights the lack of current FDA-approved treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
Study design is a small N=6 crossover trial.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The slide frames the market opportunity and clinical need for a non-oral hormone therapy.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
43
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
45
The slide highlights the clinical need for non-daily dosing progesterone delivery systems.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
46
The slide highlights a specific clinical need for breast cancer survivors.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
49
Includes regulatory disclaimer and multiple source citations.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit